Recruiting

Observational Study

Sponsor:

HemoCept Inc.

Code:

NCT07224906

Conditions

Pulmonary Hypertension

Congestive Heart Failure(CHF)

Valve Disease, Heart

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The objective of this observational pilot study is to collect HemoCept device data from subjects undergoing diagnostic right heart catheterization (RHC) procedures.

Conditions

Pulmonary Hypertension

Congestive Heart Failure(CHF)

Valve Disease, Heart

Study ID

NCT07224906

Start date

Dec 1, 2025

Status verified date

Apr, 2026

Completion date

Jan, 2027

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.
  • Subjects can be any gender but must be age 18 or older.
  • Subject is able and willing to provide informed consent and HIPAA authorization.
  • Subject is able and willing to meet all study requirements.
  • Scheduled for a diagnostic right heart catheterization (RHC-only or combined RHC+LHC; left-heart-only procedures are not eligible)

Exclusion Criteria:

  • Subject is pregnant, breastfeeding, or intends to become pregnant during this study.

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Association between device measurements and Pulmonary Capillary Wedge Pressure [ Time Frame: Day 1 ]

Central Contacts and Locations

Central contacts

Katharine Adkins

303-442-2395kathari.adkins@bch.org

Locations

Boulder Heart

Recruiting

Boulder, Colorado, United States, 80303

Contacts

Katharine Adkins

303-442-2395kathari.adkins@bch.org

Principal Investigator:

Scott Blois, MD

More Information

Sponsor

HemoCept Inc.

Last update posted

Apr 13, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by HemoCept Inc. on 2026-04-13.